I just added to my position. I have always thought the DYAX phage display technology was incredibly undervalued. It can be used to generate any kind of proteinaceous biologic, and so far RNAi has been a disappointment. I would definitely cover my shorts here, something is up. The stock hasn't moved up with this kind of volume since Kalbitor approval. I would not be surprised if DYAX were gobbled up just like Medarex and Abgenix.